Rosuvastatin (Crestor, AstraZeneca) had a higher risk rate for muscle-related side effects than five other leading statins in an analysis of seven years of FDA adverse case reports. Higher potency agents were associated with elevated relative risk of adverse events, according to researchers, who recommended that physicians consider potency when prescribing statins to manage cholesterol. The results were published online August 22 in PLOS OneTuesday, September 4, 2012
Crestor tops list for risk of muscle-related side effects
Rosuvastatin (Crestor, AstraZeneca) had a higher risk rate for muscle-related side effects than five other leading statins in an analysis of seven years of FDA adverse case reports. Higher potency agents were associated with elevated relative risk of adverse events, according to researchers, who recommended that physicians consider potency when prescribing statins to manage cholesterol. The results were published online August 22 in PLOS One
No comments:
Post a Comment